HealthBeacon SHA

Report Publication Announcement • Sep 8, 2022

National Storage Mechanism | Additional information

RNS Number : 6867Y

HealthBeacon PLC

08 September 2022

HealthBeacon launches HB Smart Pills™ Solution

Boston, 08 September 2022: HealthBeacon plc ("HealthBeacon"), the leading digital therapeutics company for injectable medications, has extended its platform to manage complex and critical pill regimens with the launch of its new HB Smart Pills Management System ("HB Smart Pills").

The announcement will be made at HealthBeacon's inaugural Vision Event in Boston later today where CEO Jim Joyce will share the Company's vision from 2022 to 2024, with an interactive product showcase of the Company's medication adherence technology following talks by global industry leaders and patient advocates on healthcare innovation using digital health technology.

The launch follows the Company's recent addition of the integrated HB Smart Scale and the partnership with the American Pharmacists Association Foundation.

The HB Smart Pills solution is an elegant device designed to fit into a patient's home managing up to nine oral medications and integrates seamlessly with the Company's existing technology platform. The innovative HB Smart Pills solution notifies the patient when prescription refills are required and records visual images of pill containers to ascertain medication adherence.

Adherence to pill regimes is a significant challenge for people with chronic illnesses managing multiple critical medications at different intervals, with up to 60% of patients globally failing to take their medications as prescribed. The U.S. oral solid dosage pharmaceutical market was valued at $214.1 billion in 2021 and is expected to exceed $420.3 billion by 2032.

Expanding the Company's product offering to now include Pill Management enables HealthBeacon to continue to roll out its technology and services through pharmaceutical companies, specialty pharmacy and governments, deepening its existing relationships and increasing its customer base.

HB Smart Pills will be available through the company's existing distribution channels in 2023.  To learn more contact HBSmartPills@HealthBeacon.com 

Commenting, HealthBeacon CEO and co-founder, Jim Joyce, said: "Today's launch of the HB Smart Pills at our inaugural Vision Event is a significant milestone for the Company on its path to becoming the world's leading digital therapeutics platform for patients managing medications in the home. Broadening our product offering and connecting HealthBeacon members to better health with digitally enabled solutions is an important step on this journey. The recent new product announcements of the HB Smart Pills and integrated Smart Scale build on the significant momentum in the business as leading pharma companies and health systems adopt our technology."

Enquiries:
HealthBeacon: Laurence Flavin	Investor.Relations@HealthBeacon.com
Goodbody (Euronext Listing Sponsor and Broker): David Kearney	+353 (1) 667 0420
Stephen Kane
Drury (Public Relations):
Cathal Barry	+353 (0) 87 227 9281
Paul Clifford	+353 (0) 87 327 2161

Ends

About HealthBeacon

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company that develops smart tools for managing medications for patients in the home. The HealthBeacon Injection Care Management System tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools, and artificial intelligence (AI) driven data analytics. Peer reviewed evidence supports a 19% improvement in therapy persistence by patients and up to 26% improvement in adherence to therapy, which improves clinical outcomes and significantly improves efficiency in health systems. The Company operates across Europe, North America and the United Kingdom and employs more than 70 people and has obtained more than 30 design and utility patents. The Company's mission is to become the world's leading digital therapeutics platform for patients managing medications in the home.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ISEEANNXEFFAEFA